Tags

Type your tag names separated by a space and hit enter

18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Clin Nucl Med. 2015 Feb; 40(2):e111-6.CN

Abstract

OBJECTIVE

The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects.

METHODS

Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software.

RESULTS

The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density.

CONCLUSIONS

In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.

Authors+Show Affiliations

From the *Nuclear Medicine Unit, CHR Orléans, †Hôpital Bretonneau, CHRU Hôpitaux de Tours; ‡INSERM U930 and Université François Rabelais de Tours; §Memory Clinic, CMRR, Hôpital Bretonneau; ‖CIC INSERM 1415; and ¶CIC-IT INSERM, CHRU Hôpitaux de Tours, Tours, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25549345

Citation

Bailly, Matthieu, et al. "18F-FDG and 18F-florbetapir PET in Clinical Practice: Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease." Clinical Nuclear Medicine, vol. 40, no. 2, 2015, pp. e111-6.
Bailly M, Ribeiro MJ, Vercouillie J, et al. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease. Clin Nucl Med. 2015;40(2):e111-6.
Bailly, M., Ribeiro, M. J., Vercouillie, J., Hommet, C., Gissot, V., Camus, V., & Guilloteau, D. (2015). 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease. Clinical Nuclear Medicine, 40(2), e111-6. https://doi.org/10.1097/RLU.0000000000000666
Bailly M, et al. 18F-FDG and 18F-florbetapir PET in Clinical Practice: Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease. Clin Nucl Med. 2015;40(2):e111-6. PubMed PMID: 25549345.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease. AU - Bailly,Matthieu, AU - Ribeiro,Maria Joao Santiago, AU - Vercouillie,Johny, AU - Hommet,Caroline, AU - Gissot,Valérie, AU - Camus,Vincent, AU - Guilloteau,Denis, PY - 2014/12/31/entrez PY - 2014/12/31/pubmed PY - 2015/9/1/medline SP - e111 EP - 6 JF - Clinical nuclear medicine JO - Clin Nucl Med VL - 40 IS - 2 N2 - OBJECTIVE: The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects. METHODS: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software. RESULTS: The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density. CONCLUSIONS: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional. SN - 1536-0229 UR - https://www.unboundmedicine.com/medline/citation/25549345/18F_FDG_and_18F_florbetapir_PET_in_clinical_practice:_regional_analysis_in_mild_cognitive_impairment_and_Alzheimer_disease_ L2 - https://dx.doi.org/10.1097/RLU.0000000000000666 DB - PRIME DP - Unbound Medicine ER -